- US Legal Forms
- Form Library
- More Forms
- More Multi-State Forms
- Regeneron Submits Biologics License Application To FDA For VEGF ...
Get Regeneron Submits Biologics License Application To FDA For VEGF ...
Ron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF TrapEye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months. Regeneron's submission includes a request for Priority Review, which, if granted, would shorte.
How It Works
-
Open form follow the instructions
-
Easily sign the form with your finger
-
Send filled & signed form or save
Experience a faster way to fill out and sign forms on the web. Access the most extensive library of templates available.
PDUFA Related content
-
Clinical Summary Review of BLA 125387/s-075
Feb 8, 2023 — Application Type Efficacy Supplement. Application Number BLA 125387...
Learn more -
Approval Package - accessdata.fda.gov
Oct 18, 2016 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
regeneron pharmaceuticals, inc.
VEGF Trap-Eye is a specially purified and formulated form of VEGF Trap for use in...
Learn more -
EX-10.1
1.9 “BLA” a Biologics License Application and amendments thereto filed pursuant to the...
Learn more -
CENTER FOR DRUG EVALUATION AND RESEARCH
Jan 27, 2014 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
Competition law and pricing among biologic drugs
by VL Van de Wiele · 2022 · Cited by 6 — The FDA accepted an abbreviated Biologics...
Learn more -
Antibodies to watch in 2022 - PMC - NCBI
by H Kaplon · 2022 · Cited by 218 — Eisai initiates rolling submission to the U.S. FDA...
Learn more -
OPT-302-1003 Date: 02 August 2018 Page 2 of 103
Regeneron. Aflibercept ophthalmic solution, Biologics License Application 125387. 2011...
Learn more -
Overview of FTC Actions in Pharmaceutical Products...
by MH Meier · 2023 · Cited by 1 — According to the complaint, Par filed an application...
Learn more -
Clinical Summary Review of BLA 125387/s-075
8 Feb 2023 — Application Type Efficacy Supplement. Application Number BLA 125387...
Learn more -
EX-99.1
We granted Regeneron an option, or the Option, to enter into an exclusive, worldwide...
Learn more -
Approval Package - accessdata.fda.gov
18 Oct 2016 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
EX-10.1
1.9 “BLA” a Biologics License Application and amendments thereto filed pursuant to the...
Learn more -
Competition law and pricing among biologic drugs
by VL Van de Wiele · 2022 · Cited by 6 — The FDA accepted an abbreviated Biologics...
Learn more -
Antibodies to watch in 2022 - PMC - NCBI
by H Kaplon · 2022 · Cited by 218 — In October 2021, Sanofi announced that the FDA...
Learn more -
OPT-302-1003 Date: 02 August 2018 Page 2 of 103
Regeneron. Aflibercept ophthalmic solution, Biologics License Application 125387. 2011...
Learn more -
Overview of FTC Actions in Pharmaceutical Products...
by MH Meier · 2023 · Cited by 1 — According to the complaint, Par filed an application...
Learn more -
A PRESCRIPTION FOR CHANGE, PART II HEARING
31 Dec 2017 — (III). C O N T E N T S. OPENING STATEMENTS. Page. Grassley, Hon. Chuck, a...
Learn more -
Clinical Summary Review of BLA 125387/s-075
Feb 8, 2023 — Application Type Efficacy Supplement. Application Number BLA 125387...
Learn more -
Approval Package - accessdata.fda.gov
Oct 18, 2016 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
EX-10.1
1.9 “BLA” a Biologics License Application and amendments thereto filed pursuant to the...
Learn more -
regeneron pharmaceuticals, inc.
VEGF Trap-Eye is a specially purified and formulated form of VEGF Trap for use in...
Learn more -
CENTER FOR DRUG EVALUATION ......
Jan 27, 2014 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
Competition law and pricing among biologic drugs
by VL Van de Wiele · 2022 · Cited by 6 — The FDA accepted an abbreviated Biologics...
Learn more -
CENTER FOR DRUG EVALUATION ......
Oct 25, 2016 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
Antibodies to watch in 2022 - PMC - NCBI
by H Kaplon · 2022 · Cited by 218 — Eisai initiates rolling submission to the U.S. FDA...
Learn more -
CENTER FOR DRUG EVALUATION ......
Aug 7, 2019 — As soon as possible, but no later than 14 days from the date of this...
Learn more -
aflibercept injection - accessdata.fda.gov
Mar 25, 2015 — This Prior Approval supplemental biologics application provides for the...
Learn more -
Antibodies to watch in 2017
by JM Reichert · 2017 · Cited by 289 — A biologics license application (BLA) for...
Learn more -
Therapies for neovascular age-related macular...
by M Hanout · 2013 · Cited by 57 — e approval of pegaptanib sodium () in December by...
Learn more -
Future of anti-VEGF: biosimilars and biobetters
Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and...
Learn more -
pharmaceutical policy in the united states in...
by AS Kesselheim · Cited by 21 — ti-VEGF Therapy in. Ophthalmology: a Qualitative...
Learn more -
(PDF) Antibodies to watch in 2021 | Hélène...
Here, the authors reviewed the status of the currently available monoclonal antibodies for...
Learn more -
Hannah Valantine Elected to National Academy of...
Jan 5, 2021 — The latest cohort of elected National Academy of Medicine members includes...
Learn more -
Review Article Current Advances in Pharmacotherapy...
by L Lu · 2018 · Cited by 42 — Currently, Iluvien is still under investigation by FDA...
Learn more -
GLOBAL LEADERSHIP IN SAVING SIGHT ANNUAL ...
Jun 30, 2016 — “There are several FDA-approved drugs that inhibit aSMase. We found...
Learn more -
2021 FACTS AND FIGURES UNIVERSITY OF COLORADO ...
FDA approval in November 2018 and regular approval in October 2020. Follow ... • Extract...
Learn more -
Antibodies to watch in 2017
by JM Reichert · 2017 · Cited by 289 — A biologics license application (BLA) for...
Learn more -
Department of Pediatrics
... VEGF-stimulated endothelial cell migration and angiogenesis; Dr. Rashmin ... insight...
Learn more -
Therapies for neovascular age-related macular...
by M Hanout · 2013 · Cited by 57 — A ibercept (, Regeneron, Tarrytown, NY, USA)...
Learn more -
pharmaceutical policy in the united states in...
by AS Kesselheim · Cited by 21 — testing begins, culminating in the submission of a new...
Learn more -
Future of anti-VEGF: biosimilars and biobetters
Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and...
Learn more -
Review Article Current Advances in Pharmacotherapy...
by L Lu · 2018 · Cited by 42 — Currently, Iluvien is still under investigation by FDA...
Learn more -
Hannah Valantine Elected to National Academy of...
Jan 5, 2021 — Industry support completed MEMRI (FDA IND), DREAM, and CAPACITY trials to...
Learn more -
(PDF) Antibodies to watch in 2021 | Hélène...
Here, the authors reviewed the status of the currently available monoclonal antibodies for...
Learn more -
GLOBAL LEADERSHIP IN SAVING SIGHT ANNUAL ...
Jun 30, 2016 — insight into how eyes normally form a drainage system to avoid fluid...
Learn more -
2021 FACTS AND FIGURES UNIVERSITY OF COLORADO ...
FDA approval in November 2018 and regular approval in October 2020. Follow-up...
Learn more -
Department of Pediatrics
consent form design, IRB and HIPAA regulatory oversight, sample acquisition, data...
Learn more -
Regeneron vegf
Regeneron Submits Biologics License Application to FDA for VEGF … ... forms of VEGF-A...
Learn more -
Clinical Summary Review of BLA 125387/s-075
Feb 8, 2023 — Application Type Efficacy Supplement. Application Number BLA 125387...
Learn more -
EX-99.1
We granted Regeneron an option, or the Option, to enter into an exclusive, worldwide...
Learn more -
Approval Package - accessdata.fda.gov
Oct 18, 2016 — Please refer to your Supplemental Biologics License Application (sBLA)...
Learn more -
EX-10.1
1.9 “BLA” a Biologics License Application and amendments thereto filed pursuant to the...
Learn more -
Competition law and pricing among biologic drugs
by VL Van de Wiele · 2022 · Cited by 6 — The FDA accepted an abbreviated Biologics...
Learn more -
Antibodies to watch in 2022 - PMC - NCBI
by H Kaplon · 2022 · Cited by 218 — On February 11, 2021, the FDA approved Evkeeza...
Learn more -
OPT-302-1003 Date: 02 August 2018 Page 2 of 103
Regeneron. Aflibercept ophthalmic solution, Biologics License Application 125387. 2011...
Learn more -
A PRESCRIPTION FOR CHANGE, PART II HEARING
Dec 31, 2017 — (III). C O N T E N T S. OPENING STATEMENTS. Page. Grassley, Hon. Chuck, a...
Learn more -
Overview of FTC Actions in Pharmaceutical Products...
by MH Meier · 2023 · Cited by 1 — complaint charged that Biovail illegally acquired...
Learn more -
Regeneron vegf
... VEGF-A and placental growth factor (PLGF), two ... Regeneron Submits Biologics License...
Learn more -
Untitled
A pharmaceutical company seeking FDA approval to sell a new prescription drug...
Learn more -
Antibodies to watch in 2017
by JM Reichert · 2017 · Cited by 289 — A biologics license application (BLA) for...
Learn more -
Therapies for neovascular age-related macular...
by M Hanout · 2013 · Cited by 57 — A ibercept (, Regeneron, Tarrytown, NY, USA)...
Learn more -
pharmaceutical policy in the united states in...
by AS Kesselheim · Cited by 21 — testing begins, culminating in the submission of a new...
Learn more -
Future of anti-VEGF: biosimilars and biobetters
Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and...
Learn more -
(PDF) Antibodies to watch in 2021 | Hélène...
Here, the authors reviewed the status of the currently available monoclonal antibodies for...
Learn more -
Review Article Current Advances in Pharmacotherapy...
by L Lu · 2018 · Cited by 42 — Currently, Iluvien is still under investigation by FDA...
Learn more -
Hannah Valantine Elected to National Academy of...
Jan 5, 2021 — Industry support completed MEMRI (FDA IND), DREAM, and CAPACITY trials to...
Learn more -
GLOBAL LEADERSHIP IN SAVING SIGHT ANNUAL ...
Jun 30, 2016 — insight into how eyes normally form a drainage system to avoid fluid...
Learn more -
2021 FACTS AND FIGURES UNIVERSITY OF COLORADO ...
FDA approval in November 2018 and regular approval in October 2020. Follow-up...
Learn more -
Department of Pediatrics
consent form design, IRB and HIPAA regulatory oversight, sample acquisition, data...
Learn more -
Regeneron vegf
Regeneron Submits Biologics License Application to FDA for VEGF … ... forms of VEGF-A...
Learn more -
Antibodies to watch in 2017
by JM Reichert · 2017 · Cited by 289 — A biologics license application (BLA) for...
Learn more -
Therapies for neovascular age-related macular...
by M Hanout · 2013 · Cited by 57 — e approval of pegaptanib sodium () in December by...
Learn more -
Future of anti-VEGF: biosimilars and biobetters
Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and...
Learn more -
pharmaceutical policy in the united states in...
by AS Kesselheim · Cited by 21 — ti-VEGF Therapy in. Ophthalmology: a Qualitative...
Learn more -
(PDF) Antibodies to watch in 2021 | Hélène...
Here, the authors reviewed the status of the currently available monoclonal antibodies for...
Learn more -
Hannah Valantine Elected to National Academy of...
Jan 5, 2021 — The latest cohort of elected National Academy of Medicine members includes...
Learn more -
Review Article Current Advances in Pharmacotherapy...
by L Lu · 2018 · Cited by 42 — Currently, Iluvien is still under investigation by FDA...
Learn more -
GLOBAL LEADERSHIP IN SAVING SIGHT ANNUAL ...
Jun 30, 2016 — “There are several FDA-approved drugs that inhibit aSMase. We found...
Learn more -
2021 FACTS AND FIGURES UNIVERSITY OF COLORADO ...
FDA approval in November 2018 and regular approval in October 2020. Follow ... • Extract...
Learn more -
Department of Pediatrics
... VEGF-stimulated endothelial cell migration and angiogenesis; Dr. Rashmin ... insight...
Learn more -
Regeneron vegf
... VEGF-A and placental growth factor (PLGF), two ... Regeneron Submits Biologics License...
Learn more
Use professional pre-built templates to fill in and sign documents online faster. Get access to thousands of forms.
Keywords relevant to Regeneron Submits Biologics License Application To FDA For VEGF ...
- fda
- intravitreal
- CRVO
- retinopathy
- 5mg
- ETDRS
- permeability
- PDUFA
- BLA
- 2mg
- 2011
- macula
- TrapEye
- neovascular
USLegal fulfills industry-leading security and compliance standards.
-
VeriSign secured
#1 Internet-trusted security seal. Ensures that a website is free of malware attacks.
-
Accredited Business
Guarantees that a business meets BBB accreditation standards in the US and Canada.
-
TopTen Reviews
Highest customer reviews on one of the most highly-trusted product review platforms.
